Dechra Pharmaceuticals PLC – LSE:DPH.L
Dechra Pharmaceuticals stock price today
Dechra Pharmaceuticals stock price monthly change
Dechra Pharmaceuticals stock price quarterly change
Dechra Pharmaceuticals stock price yearly change
Dechra Pharmaceuticals key metrics
Market Cap | 4.40B |
Enterprise value | 4.83B |
P/E | -157.73 |
EV/Sales | 6.34 |
EV/EBITDA | 77.71 |
Price/Sales | 5.78 |
Price/Book | 5.82 |
PEG ratio | -70.47 |
EPS | -0.24 |
Revenue | 761.5M |
EBITDA | 62.2M |
Income | -27.9M |
Revenue Q/Q | 15.55% |
Revenue Y/Y | 18.87% |
Profit margin | -3.66% |
Oper. margin | 2.25% |
Gross margin | 56.42% |
EBIT margin | 2.25% |
EBITDA margin | 8.17% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeDechra Pharmaceuticals stock price history
Dechra Pharmaceuticals stock forecast
Dechra Pharmaceuticals financial statements
| Sep 2022 | 188.7M | 11.3M | 5.99% |
|---|---|---|---|
| Dec 2022 | 188.7M | 11.3M | 5.99% |
| Mar 2023 | 192.05M | -25.25M | -13.15% |
| Jun 2023 | 192.05M | -25.25M | -13.15% |
| 2026 | 954M | 187M | 19.6% |
|---|
Analysts Price target
Financials & Ratios estimates
Paying a dividend while loss making.
| Payout ratio | -185.3% |
|---|
| 2016 | 1.46% |
|---|---|
| 2017 | 1.12% |
| 2019 | 1.01% |
| 2020 | 1.13% |
| 2022 | 1.2% |
| Sep 2021 | 1177700000 | 538.6M | 45.73% |
|---|---|---|---|
| Dec 2021 | 1177700000 | 538.6M | 45.73% |
| Sep 2022 | 1744300000 | 902.6M | 51.75% |
| Dec 2022 | 1744300000 | 902.6M | 51.75% |
| Sep 2022 | 25.75M | -204.1M | 160.7M |
|---|---|---|---|
| Dec 2022 | 25.75M | -204.1M | 160.7M |
| Mar 2023 | 6.05M | -9M | -2.45M |
| Jun 2023 | 6.05M | -9M | -2.45M |
Dechra Pharmaceuticals alternative data
| Aug 2023 | 1,998 |
|---|---|
| Sep 2023 | 1,998 |
| Oct 2023 | 1,998 |
| Nov 2023 | 2,457 |
| Dec 2023 | 2,457 |
| Jan 2024 | 2,457 |
| Feb 2024 | 2,457 |
| Mar 2024 | 2,457 |
| Apr 2024 | 2,457 |
| May 2024 | 2,457 |
| Jun 2024 | 2,457 |
| Jul 2024 | 2,457 |
Dechra Pharmaceuticals other data
| Insider | Compensation |
|---|---|
Mr. Ian D. Page (1961) Chief Executive Officer, MD & Executive Director | $1,250,000 |
Mr. Paul Nicholas Sandland MAAT, FCCA (1979) Chief Financial Officer & Executive Director | $704,000 |
Dr. Anthony Gerard Griffin (1963) MD of Dechra Veterinary Products for Europe & Executive Director | $643,000 |
-
What's the price of Dechra Pharmaceuticals stock today?
One share of Dechra Pharmaceuticals stock can currently be purchased for approximately $5,325.
-
When is Dechra Pharmaceuticals's next earnings date?
Unfortunately, Dechra Pharmaceuticals's (DPH.L) next earnings date is currently unknown.
-
Does Dechra Pharmaceuticals pay dividends?
Yes, Dechra Pharmaceuticals pays dividends and its trailing 12-month yield is 0.32% with -185% payout ratio.It means that the company is paying a dividend while loss making. The last Dechra Pharmaceuticals stock dividend of $0 was paid on 6 Sep 2025.
-
How much money does Dechra Pharmaceuticals make?
Dechra Pharmaceuticals has a market capitalization of 4.40B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 12.14% to 681.8M US dollars.
-
What is Dechra Pharmaceuticals's stock symbol?
Dechra Pharmaceuticals PLC is traded on the LSE under the ticker symbol "DPH.L".
-
What is Dechra Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - General industry.
-
How do i buy shares of Dechra Pharmaceuticals?
Shares of Dechra Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Dechra Pharmaceuticals's key executives?
Dechra Pharmaceuticals's management team includes the following people:
- Mr. Ian D. Page Chief Executive Officer, MD & Executive Director(age: 64, pay: $1,250,000)
- Mr. Paul Nicholas Sandland MAAT, FCCA Chief Financial Officer & Executive Director(age: 46, pay: $704,000)
- Dr. Anthony Gerard Griffin MD of Dechra Veterinary Products for Europe & Executive Director(age: 62, pay: $643,000)
-
How many employees does Dechra Pharmaceuticals have?
As Jul 2024, Dechra Pharmaceuticals employs 2,457 workers.
-
When Dechra Pharmaceuticals went public?
Dechra Pharmaceuticals PLC is publicly traded company for more then 24 years since IPO on 21 Sep 2000.
-
What is Dechra Pharmaceuticals's official website?
The official website for Dechra Pharmaceuticals is dechra.com.
-
How can i contact Dechra Pharmaceuticals?
Dechra Pharmaceuticals can be reached via phone at +44 1606 814730.
Dechra Pharmaceuticals company profile:
Dechra Pharmaceuticals PLC
dechra.comLSE
2,457
Drug Manufacturers - General
Healthcare
Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. It also provides pet nutrition products for supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. In addition, the company distributes veterinary pharmaceuticals and equipment; offers financial services; markets pet diets; and develops, regulates, manufactures, and markets crop protection. It markets its products through wholesaler and distributor networks. The company operates in the United Kingdom, Germany, rest of Europe, the United States, and internationally. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.
Northwich, CW9 7UA
:
ISIN: GB0009633180
CUSIP: G2769C145
